Sanofi’s Qfitlia seems favorable for hemophilia with easier dosing and broad coverage | ASH 2025

Sanofi is expanding options for those with hemophilia with its new treatment, Qfitlia (fitusiran). Approved this year, Qfitlia can be used for both hemophilia A and B, with or without inhibitors, making it an attractive option on the market.

The treatment is given subcutaneously rather than through an IV and can be administered as few as six times a year. Dosing begins once every two months and can be adjusted based on patient response, according to Jeff Schaffnit, general manager and head of rare blood disorders at Sanofi, who spoke with Managed Healthcare Executive about these therapies and their data, which was presented at ASH 2025.

For patients already using Helimbra (emicizumab), a treatment for hemophilia A, Sanofi is exploring ways to make switching to Qfitlia safe and effective.

“We want to make sure that if a patient is interested in switching from emicizumab to Qfitlia, that they're able to do it in a safe and effective way,” Schaffnit said.

The company has set up a trial to guide the switch and ensure patients have the right dosing and monitoring, he shared.

Payers have also generally responded positively to Qfitlia. Since its launch in March, most insurance plans have published coverage policies that match the drug’s label. The treatment is typically covered for patients aged 12 years and older for both types of hemophilia, with and without inhibitors. While prior authorization is usually required, overall pushback from payers has been minimal, Schaffnit said.

Sanofi also offers patient support through its HemAssist program. This program helps patients with copay assistance, education and access to treatment. It also provides reimbursement support for healthcare providers, aiming to reduce barriers to care and make it easier for patients to get the treatment they need.